Then, we conducted Kaplan–Meier survival analyses and found that in patients with ACC (p = 0.004), CESC (p = 0.008), LGG (p < 0.0001), LIHC (p = 0.001), MESO (p = 0.001), LUSC (p = 0.009), UVM (p < 0.0001), STAD (p = 0.001), and LAML (p = 0.014), enhanced SOAT1 expression was accompanied by poor OS outcomes (Figs. 6B–6D and 6F–6K); however, in patients with KIRC (p < 0.0001), SOAT1 was a low-risk gene (Fig. 6E). This evidence concerns the gene SOAT1 and adrenal cortex carcinoma.